Welcome to our dedicated page for NAVAN news (Ticker: NAVN), a resource for investors and traders seeking the latest updates and insights on NAVAN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NAVAN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NAVAN's position in the market.
Navan (NASDAQ: NAVN) closed its initial public offering on October 31, 2025, selling a total of 36,924,406 shares of Class A common stock at a public offering price of $25.00 per share.
The offering comprised 30,000,000 shares sold by Navan and 6,924,406 shares sold by existing stockholders; Navan did not receive proceeds from the shares sold by the selling stockholders. Underwriters were granted a 30-day option to purchase up to 5,538,660 additional shares at the IPO price, less discounts and commissions. Shares began trading on the Nasdaq Global Select Market under the symbol NAVN on October 30, 2025. Lead book-runners included Goldman Sachs and Citigroup.
FAQ
What is the current stock price of NAVAN (NAVN)?
